@entity2771 -associated renal toxicity from XXXX infusion.

@entity1 @entity2771 @entity137 @entity1011 @entity2934
OBJECTIVES: Using data from @entity1 who developed elevations in serum @entity1011 concentrations while receiving continuous-infusion @entity2934 , we sought to determine the correlations between the magnitude of serum @entity1011 concentration rise and each of the following variables: serum @entity2771 level, cumulative @entity2934 dose, and duration of @entity2934 administration. An additional objective was to identify clinical markers for @entity2771 @entity137 . DESIGN: Retrospective chart review. SETTING: Medical-surgical intensive care unit and burn unit at a university hospital. @entity1 : Eight @entity1 who developed elevations in serum @entity1011 concentrations while receiving continuous-infusion @entity2934 (range 2-28 mg/hr). MEASUREMENTS AND MAIN RESULTS: The mean cumulative dose of @entity2934 was 4305 mg (range 1200-10,920 mg), and the mean @entity2771 level determined at the time of peak serum @entity1011 concentration was 1103 microg/ml (range 186-3450 microg/ml). Serum @entity1011 concentrations increased in all eight @entity1 during @entity2934 infusion and decreased in seven within 3 days after stopping infusion. A weak-to-moderate correlation existed between the magnitude of the rise in serum @entity1011 concentration and @entity2771 level (r=0.53). A weak-to-moderate correlation also was identified between cumulative @entity2934 dose and magnitude of serum @entity1011 concentration rise (r=0.43), and a strong-to-moderate correlation was found between duration of @entity2934 infusion and magnitude of serum @entity1011 concentration rise (r=0.60). @entity2771 levels were strongly correlated with both serum osmolality and osmol gap. CONCLUSION: The patients' increased serum @entity1011 concentrations are likely to have resulted from exposure to @entity2771 as a result of @entity2934 infusion. Serum osmolality and osmol gap may be useful markers for @entity2771 @entity137 .
